Next Article in Journal
Cardiopulmonary Exercise Testing in Children and Young Adolescents after a Multisystem Inflammatory Syndrome: Physical Deconditioning or Residual Pathology?
Previous Article in Journal
Relationship between Muscle Mass, Bone Density and Vascular Calcifications in Elderly People with SARS-CoV-2 Pneumonia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 6
10.3390/jcm12062374
Review Report
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Pretreatment with P2Y12 Receptor Inhibitors in Acute Coronary Syndromes—Is the Current Standpoint of ESC Experts Sufficiently Supported?

J. Clin. Med. 2023, 12(6), 2374; https://doi.org/10.3390/jcm12062374
by Piotr Niezgoda 1,*, Małgorzata Ostrowska 1, Piotr Adamski 1, Robert Gajda 2 and Jacek Kubica 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2023, 12(6), 2374; https://doi.org/10.3390/jcm12062374
Submission received: 30 December 2022 / Revised: 22 February 2023 / Accepted: 16 March 2023 / Published: 19 March 2023
(This article belongs to the Section Cardiology)

Round 1

Reviewer 1 Report

It is a well written article and is relevant to the current clinical practice. 

I have some minor suggestions

1. The authors should briefly discuss the rationale for pretreatment with a P2Y12 receptor blockers with the respect to achieving superior and early platelet inhibition. The authors should discuss early GPIIb/IIa trials followed by PCI-CURE trial that provided evidence for pretreatment with cloipdogrel. Since clopidogrel requires upto 24 hours with 300 mg LD or nearly 5-7 days with 75 mg MD, this trial demonstrated the use of pretreatment. However, loading dose of prasugrel or ticagrelor requires only 1-2 hours to achieve superior platelet inhibition, pretreatment may not be necessary. The authors should discuss this briefly in the introduction. 

Moreover, the potential role of new P2Y12 receptor inhibitor, selatogrel. This agent is associated with fast and irreversible P2Y12 inhibition and may be a best option for pretreatment. This can be self administered as a subcutaneous injection. 

Another concern is there are many mistakes in  grammar  that should be addressed. Please see attached file for further comments 

Comments for author File: Comments.pdf

Author Response

Dear Reviewer,

please find enclosed a document with replies to your review.

Best regards,

Piotr Niezgoda

Author Response File: Author Response.docx

Reviewer 2 Report

Pretreatment in ACS, especially in NSTEMI si always a question in ER and situantions when patient doesnt go to coronary angiography immediately.
Authors gave a good review of current research and guidelines. However, this is a complex area of investigation and summary, conclusion should be more thoroughly discussed (in view of this question that were raised by author themselves).

Author Response

Dear Reviewer,

Please find enclosed a document with the reply to your review.

Best regards,

Piotr Niezgoda

Author Response File: Author Response.docx

Back to TopTop